Migraine Drugs Industry Therapeutics, Industry Size, Competitive Share and Major Growth Drivers
Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.
According to MRFR Latest Research analysis, The Global Migraine Drugs Industry is expected to hold a value of USD 6.5 Billion by 2025 at a CAGR of 5.9%. and was valued at USD 4.4 billion in 2018.
Avail Free Sample Here: https://www.marketresearchfuture.com/sample_request/8379
Major Key Players Competitive Dashboard:
The global Migraine Drugs Industry is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. Migraine treatment drugs available are approved for the acute form of the condition, led by generic triptans as the first-line treatment.
Some of the key players in the global Migraine Drugs Industry are Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca Plc (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc (US), Eli Lilly and Company, and eNeura Inc.
The global Migraine Drugs Industry has been segmented based on type, treatment, drug class, and end user.
on the basis of migraine-type into episodic migraine and chronic migraine.
on the basis of treatment type, into, acute, preventive, neuromodulation, and others.
on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.
on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others.
Browse Complete 100 Pages Premium Research Report along with Detailed TOC at: https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The Migraine Drugs Industry in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312